Cyclooxygenase-2 in carcinogenesis of the gastrointestinal tract

Scandinavian Journal of Gastroenterology

Volumn 36, Issue 9, 2001, Pages 897-903

  Van Rees, B P ^a   Ristimaki A ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; CYTOKINE; MESSENGER RNA;

ADENOCARCINOMA; CARCINOGENESIS; CYTOKINE PRODUCTION; ENZYME ACTIVITY; ESOPHAGUS CARCINOMA; GASTROINTESTINAL CARCINOMA; HISTOPATHOLOGY; HUMAN; MOLECULAR CLONING; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA;

EID: 0034919097     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365520121464     Document Type: Review

References (109)

1. Cyclooxygenases 1 and 2
2. Cyclooxygenase in biology and disease
3. Cyclooxygenase-2 inhibitors in tumorigenesis (Part I)
4. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II)
5. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis
6. Cancer mortality in patients with rheumatoid arthritis
7. Incidence of cancer among patients with rheumatoid arthritis
8. Aspirin use and risk of fatal cancer
9. Aspirin, NSA1Ds, and digestive tract cancers
10. The role of nonsteroidal anti-inflammatory drugs in colorectal cancer prevention
11. Aspirin
12. Barrett's esophagus and esophageal adenocarcinoma. Endoscopic and histologic surveillance
13. Barett's oesophagus: Pathophysiology, diagnosis, and management
14. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas
15. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure
16. Cyclooxygenase-2 expression in human esophageal carcinoma
17. Dihydroxy bile acids activate the transcription of cyclooxygenase-2
18. Expression of cyclooxygenase-2 in human squamous cell carcinoma of the esophagus; an immunohistochemical survey
19. Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus
20. Further studies on the therapeutic effect of indomethacin on esophageal tumors
21. Molecular epidemiology, pathogenesis and prevention of gastric cancer
22. The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma
23. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts
24. Expression of cyclooxygenase-2 in human gastric carcinoma
25. 2, cyclo-oxygenases and arachidonate in human stomach tumors
26. Expression of cyclooxygenase-2 protein in gastric adenocarcinoma
27. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma
28. Overexpression of cyclooxygenase-2 protein is less frequent in gastric cancers with microsatellite instability
29. Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer
30. Expression of cyclooxygenase-2 in human adenocarcinomas of the gastric cardia and corpus
31. Increased expression of cyclooxygenase-2 protein in human gastric carcinoma
32. Reduced COX-2 protein in colorectal cancer with defective mismatch repair
33. Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions
34. Localisation of cyclooxygenase 1 and cyclooxygenase 2 in Helicobacter pylori related gastritis and gastric ulcer tissues in humans
35. Cyclooxygenase (COX) 1 and 2 in normal, inflamed, and ulcerated human gastric mucosa
36. 2 synthesis in MKN 28 gastric mucosal cells in vitro
37. Role of cyclooxygenase-2 in Helicobacter pylori-induced gastritis in mongolian gerbils
38. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo
39. Tumorigenic transformation of immortalized ECV endothelial cells by cyclooxygenase-1 overexpression
40. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
41. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing
42. Effects of NSAIDs on NNK-induced pulmonary and gastric tumorigenesis in A/J mice
43. Inhibition by aspirin of N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide-induced bladder carcinogenesis and enhancement of forestomach carcinogenesis
44. Gastric carcinogenesis: A model for the identification of risk factors
45. 2 on gastrointestinal tumorigenesis induced by N-methyl-N′-nitro-N-nitrosoguanidine in rats: Glandular epithelium of stomach and duodenum
46. Evidences for involvement of cyclooxygenase-2 in proliferation of two gastrointestinal cancer cell lines
47. Effects of NSAIDs on proliferation of gastric cancer cells in vitro: Possible implication of cyclooxygenase-2 in cancer development
48. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice
49. Aspirin use and potential mechanisms for colorectal cancer prevention
50. Non-steroidal anti-inflammatory drugs and the chemoprevention of gastrointestinal cancers
51. Chemoprevention of colorectal cancer through inhibition of cyclooxygenase-2
52. The role of cyclooxygenases in inflammation, cancer, and development
53. The Fourth DeWitt S. Goodman lecture. Novel approaches to the prevention of colon cancer by nutritional manipulation and chemoprevention
54. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis
55. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis
56. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the Min mouse model of adenomatous polyposis
57. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis
58. Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)
59. Cyclooxygenase knockout mice: Models for elucidating isoform-specific functions
60. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice
61. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
62. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
63. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer
64. Expression of cyclooxygenase-1 and -2 in human colorectal cancer
65. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: Evidence for a transcriptional effect
66. Differential expression of cyclooxygenase 2 in human colorectal cancer
67. Aberrant methylation of the Cyclooxygenase 2 CpG island in colorectal tumors
68. Localization of cyclooxygenase-2 in human sporadic colorectal adenomas
69. Cyclooxygenase 2 expression is increased in the stroma of colon carcinomas from IL-10(-/-) mice
70. Cyclooxygenase-2 overexpression correlates with tumor recurrence, especially haematogenous metastasis, of colorectal cancer
71. COX-2 in murine intestinal tumors
72. Host cyclooxygenase-2 modulates carcinoma growth
73. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2
74. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential
75. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients
76. The relationship between cyclooxygenase-2 expression and colorectal cancer
77. Basal expression of cyclooxygenase-2 and nuclear factor-interleukin 6 are dominant and coordinately regulated by interleukin 1 in the pancreatic islet
78. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: Growth inhibition by nonsteroidal anti-inflammatory drugs
79. Overexpression of cyclooxygenase-2 in carcinoma of the pancreas
80. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer
81. Immunohistochemical analysis of cyclooxygenase-2 expression in pancreatic tumors
82. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas
83. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: Relevance to tumor dedifferentiation
84. Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma
85. Cyclooxygenase-2 expression in hepatocellular carcinoma
86. Aspirin use and lung, colon, and breast cancer incidence in a prospective study
87. Aspirin and reduced risk of esophageal carcinoma
88. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer
89. Aspirin protects against gastric cancer: Results of a case-control study from Moscow, Russia
90. Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel
91. Aspirin use and colorectal cancer: Post-trial follow-up data from the Physicians' Health Study
92. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors
93. The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal antiinflammatory drugs (NSAIDs)
94. Role of BAX in the apoptotic response to anticancer agents
95. Cancer research: Anti-inflammatories inhibit cancer growth - But how?
96. The inducible prostaglandin biosynthetic enzyme, cyclooxygenase 2, is not mutated in patients with attenuated adenomatous polyposis coli
97. Germline alterations in the cyclooxygenase-2 gene are not associated with the development of extracolonic manifestations in a large Swiss familial adenomatous polyposis kindred
98. A selective cyclooxygenase 2 inhibitor suppresses the growth of H-ras-transformed rat intestinal epithelial cells
99. Transcriptional activation of cyclooxygenase-2 in Wnt-1-transformed mouse mammary epithelial cells
100. Inhibition of cyclooxygenase-2 gene expression by p53
101. Regulation of cyclooxygenase-2 pathway by HER2 receptor
102. Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts
103. Combinatorial chemoprevention of intestinal neoplasia
104. Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme
105. Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines
106. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor
107. Retinoids suppress epidermal growth factor-induced transcription of cyclooxygenase-2 in human oral squamous carcinoma cells
108. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos
109. Expression of cyclooxygenase-2 in dysplasia of the stomach and in intestinal type gastric adenocarcinoma